通道阻断剂通过调节炎症因素来影响血管生成:随机对照试验的元分析
Jianwei Ge1, Menglin Sun1,2, Shuo Yang1
1Department of Anesthesiology, Third Affiliated Hospital of Zhengzhou University, ZhengZhou, China.
European journal of medical research
|March 7, 2026
概括
通道阻塞剂显著减少炎症因素,包括IL-1,IL-6和TNF-α,从而抑制病态血管生成. 这一元分析证实了它们在各种条件下具有抗血管和抗炎作用.
科学领域:
- 细胞生物学 细胞生物学
- 生理学 生理学 生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 新血管化涉及刺激和抑制血管生成的因素,对于生理血管形成至关重要.
- 病理性血管生成有助于疾病的发展.
- 离子对于细胞功能至关重要,包括基因表达,细胞周期,运动性,亡和自.
研究的目的:
- 通过检查它们对炎症因素的影响来评估通道阻塞剂对血管生成的影响.
- 综合随机对照试验中关于通道阻断剂在血管生成调节中的作用的证据.
主要方法:
- 进行了一项元分析,搜索了8个主要数据库,截至2024年6月.
- 包括随机对照试验,比较血管新生和炎症研究中的实验组和对照组.
- 在治疗前后分析IL-1,IL-6和TNF-α水平的差异.
主要成果:
- 包括九项试验,在基线炎症因子水平中没有异质性.
- 与对照组相比,通道阻断剂治疗显著降低了IL-1 (效果大小为23.26),IL-6 (-37.19) 和TNF-α (-55.51).
- 这些减少在统计学上是显著的 (P<0.05).
结论:
- 炎症因子IL-1,IL-6和TNF-α在血管再生中起作用.
- 通道阻塞剂通过调节缺氧诱导因素来影响血管生产.
- 通道阻塞剂显著减少炎症因子分泌,从而抑制血管生成.
相关概念视频
Antihypertensive Drugs: Action of Calcium Channel Blockers
2.0K
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
2.0K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.7K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K
Regulation of Angiogenesis and Blood Supply
3.8K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K
Mechanism of Angiogenesis
7.3K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
609
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
609


